Tuberculosis Diagnostics Market Report 2026

Tuberculosis Diagnostics Market Overview

• Tuberculosis Diagnostics market size has reached to $2.34 billion in 2025 • Expected to grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Rise In Incidence Of Tuberculosis Driving Market Growth Due To Increased Need For Early Detection And Accurate Diagnosis • Market Trend: Product Innovations Driving Tuberculosis Diagnostics • Asia-Pacific was the largest region in 2025.

What Is Covered Under Tuberculosis Diagnostics Market?

Tuberculosis diagnostics refers to a tool or test with high sensitivity and specificity for TB diagnosis and tracking the effectiveness of treatment. Tuberculosis diagnostics are used to identify acid-fast bacilli (AFB) in clinical specimens and to detect tuberculosis. The various types of tuberculosis diagnostic markets include radiographic testing, laboratory testing, nucleic acid testing, cytokine detection testing, drug resistance testing, skin test or Mantoux test (TST), blood/serology test, smear microscopy tests, cell culture-based tests, and others. Radiographic tests are used to detect chest abnormalities in the case of tuberculosis symptoms. The radiographic test refers to the diagnosis of lesions that may develop anywhere in the lungs and vary in terms of cavitation, density, size, and shape. The tests include nucleic acid testing (NAT), skin testing or Mantoux test (TST), blood testing or serology tests, smear microscopy, cultured-based tests, radiography tests, and others, used for disease stages such as latent tuberculosis and active tuberculosis. The end-users of tuberculosis diagnostics include hospitals and diagnostic laboratories, physician’s office laboratories, reference laboratories, academic institutions, and research facilities.

What Is The Tuberculosis Diagnostics Market Growth Forecast?

The tuberculosis diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing demand for rapid and accurate tb diagnosis, rising focus on drug-resistant tb detection, expansion of decentralized diagnostic testing, increasing investments in molecular diagnostics, integration of ai-assisted diagnostic tools. Major trends in the forecast period include increasing adoption of molecular tb testing methods, rising use of rapid diagnostic platforms, growing integration of drug resistance detection, expansion of point-of-care tb testing, enhanced focus on high-sensitivity diagnostics.

What Is The Driver Of The Tuberculosis Diagnostics Market?

The rise in the incidence of tuberculosis is driving the demand for the tuberculosis diagnostics market going forward. Tuberculosis (TB) is a contagious bacterial infection primarily affecting the lungs which requires timely detection to prevent severe complications and transmission. The rise in the incidence of tuberculosis (TB) is due to the increasing prevalence of HIV/AIDS, which severely compromises the immune system and makes individuals highly susceptible to developing active tuberculosis disease. The increase in the incidence of tuberculosis supports the tuberculosis diagnostics by boosting demand for rapid, accurate, and point-of-care diagnostic tests that enable early treatment initiation and better disease management. For instance, in October 2025, according to the UK Health Security Agency, a government agency responsible for all health security in England, Tuberculosis levels in England increased by 13.6 percent in 2024 compared with 2023, with 5,490 notifications reported in 2024 compared to 4,831 in 2023. Therefore, the rise in the incidence of tuberculosis is driving the growth of the tuberculosis diagnostics industry.

Key Players In The Global Tuberculosis Diagnostics Market

Major companies operating in the tuberculosis diagnostics market are Beckton Dickinson and Company, F. Hoffmann-La Roche Ltd, Qiagen N.V, BioMerieux SA, Danaher Corporation, PerkinElmer, Thermo Fisher Scientific Inc., Creative Diagnostics, Lionex GmbH, Biocartis, Bio-Rad Laboratories India Pvt.Ltd, Zhejiang Di'an Diagnostics Technology Co. Ltd, Kindstar Global, Siemens AG, LumiraDx Limited, TestLine Clinical Diagnostics s.r.o., Hologic, Meridian Bioscience, Abbott Laboratories Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc, Akonni Biosystems Inc, Epistem Limited, Gen-Probe, Bio Certica, BixBio

Global Tuberculosis Diagnostics Market Trends and Insights

Major companies operating in the tuberculosis diagnostics market are focusing on product innovations and developing new product solutions, such as tuberculosis diagnostic tests, to strengthen their position in the market. Tuberculosis diagnostic tests refer to medical examinations and laboratory techniques used to detect whether a person is infected with Mycobacterium tuberculosis, the bacteria that cause TB. These tests help identify active TB disease, latent TB infection, and drug-resistant strains so that appropriate treatment can begin promptly. For example, in February 2023, Redcliffe Labs, an India-based technology-empowered diagnostics service provider, launched the BD MAX MDR TB (Tuberculosis) test, a diagnostic test to enable clinicians to rapidly test for tuberculosis and multidrug resistance as a first-line test, which is performed on BD MAX molecular diagnostic system. Clinicians use the test to simultaneously detect bacteria that cause TB and determine if the bacteria contain mutations associated with resistance to two important first-line drugs, Isoniazid (INH) and Rifampicin (RIF).

What Are Latest Mergers And Acquisitions In The Tuberculosis Diagnostics Market?

In August 2023, Danaher Corporation, a US-based science and technology company, acquired Abcam plc, foran undisclosed amount. With this acquisition, Danaher Corporation seeks to strengthen its position in the life sciences sector by leveraging Abcam plc's extensive portfolio of high-quality reagents and antibodies, thereby enhancing its capabilities in scientific research and development to better serve the growing demand for advanced biological research tools. Abcam plc isa UK-based biotechnology company that offers tuberculosis diagnostics.

What Defines the Tuberculosis Diagnostics Market?

The tuberculosis diagnostics market includes revenues earned by entities by providing services related to diagnostic laboratory methods, detection of latent infection, detection of drug resistance, and diagnostic laboratory testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tuberculosis Diagnostics Market Report 2026?

The tuberculosis diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tuberculosis diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.